New drug UCB0022 tested for safety in healthy people
NCT ID NCT06970301
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a new drug called UCB0022 (glovadalen) in 32 healthy adults from Caucasian, Japanese, and Chinese backgrounds. Participants received either the drug or a placebo in increasing doses. The study is complete and focused on checking for side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glovadalen (UCB0022)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY STUDY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Up0135 1001
Glendale, California, 91206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.